BridgeBio Pharma (FRA:2CL) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


FRA:2CL BridgeBio Pharma Inc FRA:2CL
66 GF Score
Price €60.30
GF Value €121.36
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is BridgeBio Pharma Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

BridgeBio Pharma's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

FRA:2CL vs EXEL, IONS, SMMT: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, BridgeBio Pharma's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BridgeBio Pharma Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BridgeBio Pharma's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where BridgeBio Pharma's Margin of Safety % (DCF Earnings Based) falls into.


FRA:2CL
66GF Score
BridgeBio Pharma Inc FRA:2CL
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BridgeBio Pharma (FRA:2CL) Overvalued in 2026?

Based on GuruFocus' analysis, BridgeBio Pharma stock appears to be undervalued. The current stock price of €60.30 is trading 50.3% below its estimated GF Value™ of €121.36. GuruFocus considers BridgeBio Pharma to be Possible Value Trap.

Key valuation signals for FRA:2CL:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €121.36 vs. price of €60.30 (50.3% below fair value)
  • GF Score™: 66/100 with 7 warning signs

No single metric tells the full story. See the FRA:2CL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BridgeBio Pharma Business Description

Other Exchanges BBIO:USA1BBIO:Italy
Address 3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
66GF Score

Get the complete analysis for FRA:2CL

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€60.30
Price
€121.36
GF Value